DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA561092
Title:
Biochemical Markers of Brain Injury: An Integrated Proteomics-Based Approach
Descriptive Note:
Final rept. 15 Jul 2007-30 Nov 2011
Corporate Author:
BANYAN BIOMARKERS INC ALACHUA FL
Report Date:
2011-12-01
Pagination or Media Count:
21.0
Abstract:
The objective of this study was to identify and characterize biochemical markers of penetrating ballistic brain injury PBBI. Candidate biomarkers were examined in a rat model for PBBI, with the goal of producing a panel of diagnostic and therapeutic-tracking biomarkers for penetrating brain injury. ELISA assays were developed and optimized to validate the biomarkers for PBBI. To assess the relationship between injury magnitude and biomarker levels, PBBI-treated rats were generated at three discreet injury magnitudes 5 moderate, 10 severe, 12.5 delayed lethal, plus controls. Levels of four biomarkers SBDP150, SPDP145, UCHL1, GFAP were measured in collected biofluids andor cortex, using our ELISAs and immunoblotting. We found that SBDP150 levels were significantly elevated at early times after PBBI in CSF and blood-derived plasma. UCHL1 was also elevated in early plasma samples, making SBDP150 and UCHL1 candidates for diagnosing severe PBBI in acute settings from a blood sample. Levels of all four biomarkers showed stepwise increases in biofluids andor cortex as injury magnitude increased. Additionally, GFAP levels in the CSF were lowered by treatment of PBBI animals with drugs, indicating that GFAP is a useful biomarker for monitoring progress after therapeutic interventions. Overall, our results robustly support the conclusion that biomarkers are effective indicators of PBBI that can track injury magnitude and therapeutic progress. Results are reported here in full.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
